Respiratory syncytial virus (RSV) has been described as a pathogen responsible for severe respiratory tract infections in solid-organ transplant recipients.[@bib1] Lung transplant recipients (LTRs) are the most frequently infected transplant patients.[@bib1], [@bib2], [@bib3] RSV infections in LTRs have been associated with mortality rates of 10% to 20%.[@bib1], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7] Immunoglobulins, ribavirin, and palivizumab have been suggested both for therapeutic and pre-emptive approaches to RSV infections in LTRs. However, no placebo-controlled trial has clearly established their indication and efficacy in this population. Moreover, their widespread use is limited by concerns of toxicity (mainly nephrotoxicity) and elevated costs. Recommendations are few, often controversial, and have been established primarily for bone marrow transplant (BMT) recipients.[@bib4], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17] Little has been published on the treatment of RSV infection in solid-organ transplant recipients.[@bib5], [@bib6], [@bib18] Official recommendations specifically for the management of RSV in transplant patients are available only in a few countries, such as the United States,[@bib4] Sweden,[@bib19] and Switzerland.[@bib20] In Switzerland, pre-emptive therapy in cases of low-grade immunosuppression, prophylaxis in severe immunosuppression, and combined treatment with immunoglobulin (Ig), ribavirin, and palivizumab in cases of proven infection have been suggested for both BMT recipients and LTRs.[@bib20]

To get a better overview on the clinical evolution of RSV infections in LTRs we retrospectively searched our virology reports and identified 10 adult LTRs with proven lower respiratory tract RSV infection.[@bib11] Herein we describe their clinical evolution according to treatment.

Methods {#sec1}
=======

Setting {#sec1.1}
-------

The study was conducted at the Hôpitaux Universitaires de Genève (HUG) and Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland. Both hospitals belong to the "Centre Universitaire Romand de Transplantation," which performed 194 LTRs since 1993. Both hospitals use similar immunosuppressive regimens with initial anti--interleukin-2R induction, and long-term triple associations, including either cyclosporine (trough target levels between 150 and 200 μg/liter), tacrolimus (trough target levels between 10 and 15 μg/liter), or everolimus (trough target levels between 3 and 15 μg/liter), with mycophenolate mofetil (2 × 1 g/day) and low-dose prednisone (5 to 25 mg/day).

Case findings and virologic diagnosis {#sec1.2}
-------------------------------------

Since 2003, all LTRs have been followed in a prospective cohort study (*n* = 77). We identified all cases of lower respiratory tract infection due to RSV in LTRs from 2003 to March 2006 in patients hospitalized for respiratory tract infection who underwent bronchoalveolar lavage (BAL, *n* = 343) assessment. All BAL fluid specimens[@bib21], [@bib22] were processed in a standardized manner, according to local[@bib21], [@bib22] and international guidelines.[@bib15], [@bib23], [@bib24] Specimens for histology were sampled and standard microbiologic techniques were employed to test for the presence of aerobic and anaerobic bacteria, mycobacteria, fungi, and *Pneumocystis jiroveci* in respiratory secretions. Before 2006, all viral pathogens were detected by culture. Since 2006, an in-house[@bib22] real-time reverse-transcription polymerase chain reaction (PCR)[@bib23] in BAL fluid specimens was used to detect the presence of influenza A and B, RSV A and B, parainfluenza virus 1 and 3, human rhinovirus, enterovirus, coronaviruses OC43, NL63, and 229E and HKU1, and human metapneumovirus,[@bib22] whereas cytomegalovirus, adenovirus, herpes simplex virus, *Legionella* sp, *Mycoplasma* sp, and *Chlamydia* sp continued to be detected by culture and/or regular specific PCRs. Patient charts of identified cases were retrospectively reviewed for symptoms, treatments, and clinical evolution. No serologic investigations were performed.

Results {#sec2}
=======

The 77 LTRs in our cohort witnessed a total of 68 viral respiratory tract infections between November 2003 and March 2006, including 10 episodes with respiratory secretions positive for RSV in 10 patients (7 men and 3 women, age range 28 to 64 years). Thus, RSV accounted for 14.7% of these viral respiratory infections. Diagnosis of RSV was established by viral culture in 4 patients, by PCR in 5 cases, and by both techniques in 1 patient. No other concomitant viral pathogens were found. In addition, in 1 LTR, RSV was detected by PCR during an annual control in the absence of any respiratory symptoms. This patient was excluded from analysis. None of our patients had a secondary respiratory specimen positive for RSV in later time periods.

The clinical characteristics of the 10 cases are presented in detail in [Table 1](#tbl1){ref-type="table"}. All patients were symptomatic for community-acquired respiratory tract infection at the time of their positive respiratory tract specimen. All episodes occurred during the winter and early spring, without any epidemiologic inter-case link. Seven episodes occurred at least 1 year after transplantation, 2 occurred at 6 months, and 1 occurred at 15 days (range 15 to 144 days post-transplantation). Three patients had a concomitant biopsy-proven allograft rejection[@bib25]: Patients 3 and 7 had acute Grade A3 rejection and were treated with anti-thymocyte globulins and intravenous methylprednisolone, respectively, and Patient 5 had acute Grade A1 rejection that did not require specific anti-rejection therapy. Two patients had concomitant infection requiring specific therapy: Patient 1 had a bacterial pneumonia, and Patient 10 had a symptomatic cytomegalovirus (CMV) disease. Patient 6 was treated for an asymptomatic concomitant low-grade re-activation of CMV replication. A new infiltrate on the chest X-ray was noted for 3 patients (Patients 4, 6, and 8). Individual evolution data for forced expiratory volume in 1 second (FEV~1~) are shown in [Table 2](#tbl2){ref-type="table"}. Compared with 1 month prior to RSV infection, the FEV~1~ changes ranged from +5% to −42%, with only 2 patients having a \>10% FEV~1~ reduction (Patients 4 and 7). Four patients never recovered their pre--RSV infection FEV~1~ value (Patient 5: −5%; Patient 6: −8.3%; Patient 8: −10.9%; and Patient 9: −3.7%).Table 1Clinical Characteristics of 10 Cases of RSV Infection in Lung Transplant RecipientsCase 1Case 2Case 3Case 4Case 5Case 6Case 7Case 8Case 9Case 10GenderFemaleMaleFemaleMaleMaleFemaleMaleMaleMaleMaleIndication for transplantationα~1~-anti-trypsin deficiencyCystic fibrosisLymphangioleiomyomatosisCOPDCOPDIdiopathic pulmonary fibrosisα~1~-anti-trypsin deficiencyPulmonary hypertensionCOPDBronchioalveolar carcinomaType of transplantationDoubleDoubleDoubleHeart--lungDoubleSingleDoubleDoubleSingleDoubleAge at diagnosis (years)54284862586264586347Time after lung transplantation (months)366654481444812720.5Clinical symptoms at hospitalizationRhinitis, coughRhinitis, cough, feverRhinitis, coughRhinitis, cough, dyspnea, fever, rigors, myalgia, wheezingRhinitis, progressive dyspneaRhinitis, cough, sputum, orthopneaDyspnea, coughCoughRhinitis, cough, pharyngitisCoughPeriod/monthFebruaryJanuaryMarchDecemberMarchMarchDecemberAprilAprilAprilRSV detectionPCR in BALPCR in BALPCR and viral culture in BALViral culture in BALViral culture in BALViral culture in BALViral culture in BALPCR in BALPCR in BALPCR in BALSpecific anti-RSV treatmentNoNoRibavirin, palivizumabNoNoRibavirin, palivizumabNoNoNoNoMechanical ventilationNoNoNoNoNoYes (17 days)NoNoNoNoConcomitant pathology10^5^ CFU/ml of *S aureus* and *S marcescens*NoAcute Grade A3 allograft rejectionNoAcute Grade A1 allograft rejectionAsymptomatic CMV replicationAcute Grade A3 allograft rejectionLymphocytic alveolitisNoSymptomatic CMV diseaseChest radiologyNormalNormalNormalGround-glass opacitiesNormalInterstitial infiltratePre-existing right pleural effusionInterstitial infiltrateNormalNormalImmediate outcomeRecoveryRecoveryRecoveryRecoveryRecoveryRecoveryRecoveryRecoveryRecoveryRecoveryLong-term outcomeAlive at 40 monthsDied of bacterial infection after 35 monthsDied of chronic rejection after 22 monthsAlive at 54 monthsDied of chronic rejection after 39 monthsDied of AML and MRSA pneumonia after 8 monthsAlive at 54 monthsAlive at 74 monthsAlive at 75 monthsAlive at 50 months[^1]Table 2FEV~1~ Before and After RSV Infection in Lung Transplant RecipientsCase 1Case 2Case 3Case 4Case 5Case 6Case 7Case 8Case 9Case 10Best FEV~1~ before RSV infection3.724.392.293.075.112.722.523.772.432.49FEV~1~ 1 month before RSV infection3.214.192.292.624.01.091.683.662.172.49FEV~1~ at RSV infection3.313.792.161.364.01.040.933.592.28NAFEV~1~ change (%) at RSV infection+3%−10%−6%−42%0%−5%−41%−2%+5%NAFEV~1~ 1 month after RSV infection3.464.242.412.713.81.01.383.26NA2.9Best FEV~1~ after RSV infection3.684.243.332.763.81.01.753.262.093.39BOS stage before RSV infection0000p122000BOS stage after RSV infection (last available)0p130p322110Number of acute rejection episodes after RSV infection0330604110

All patients recovered from their RSV infection. Eight of the 10 patients already had clinical improvement at the time of RSV diagnosis. In 2 of these patients the immunosuppression had been temporarily reduced; however, no patient was given specific RSV treatment. Strikingly, this group included 7 patients who concomitantly received methyprednisolone for a rejection episode and had an FEV~1~ reduction of 41%; Patient 4 also had a transient FEV~1~ reduction of 42%. Two patients were treated with ribavirin for 7 days (orally with 1,600 mg/day or intravenously with 10 mg/kg 3 times daily) concomitant with intravenous palivizumab (a single dose of 15 mg/kg) ([Table 1](#tbl1){ref-type="table"}), including Patient 3, who required anti-thymocyte globulins for non-responding concomitant allograft rejection, and Patient 6, who had clinically severe disease requiring mechanical ventilation (pre-RSV FEV~1~ = 1.09). Prior to RSV infection, 6 patients had bronchiolitis obliterans syndrome (BOS) Stage 0, whereas 2 patients (Patients 6 and 7) had a BOS Stage 2 ([Table 2](#tbl2){ref-type="table"}). Post-RSV worsening of the BOS staging occurred in 6 patients (Patients 1, 2, 3, 5, 8 and 9), compared with the overall incidence of BOS (independently of RSV infection) in our LTR cohort of 33.5%. Post--RSV infection acute rejection episodes occurred in 6 patients ([Table 2](#tbl2){ref-type="table"}). Four patients had ≥3 rejection episodes, including Patients 2, 3, and 5, who had a worsened BOS stage.

Discussion {#sec3}
==========

The detection of RSV by PCR in respiratory secretions is highly sensitive and specific,[@bib24] and is currently considered the best available test for the diagnosis of respiratory tract infections in adult lung transplant recipients.[@bib15], [@bib20], [@bib21], [@bib23] It has been implemented in many lung transplant centers and may increase the number of patients diagnosed with RSV infections. Therefore, guidelines are needed to help clinicians decide whether all LTRs with documented RSV require specific treatment. Herein we have reported 10 cases of proven community-acquired lower respiratory tract RSV infections in adult lung transplant recipients. Surprisingly, as a result of delayed diagnosis, 8 of them had already improved clinically before the diagnosis of RSV infection was made. These patients therefore recovered without receiving specific anti-RSV therapy. In only 2 of these cases was the immunosuppression temporarily reduced. In 1 patient a new ground-glass opacity on computed tomography scan[@bib18], [@bib26], [@bib27] (for which no other cause than RSV was found) cleared spontaneously. As previously described in BMT recipients,[@bib8], [@bib10] RSV can also be recovered from the lung of asymptomatic lung transplant recipients.[@bib28] Indeed, an eleventh, asymptomatic patient not included in this case description had a positive RSV PCR in an annual control BAL assessment. He remained clinically stable without any treatment. This case illustrates a possible detection bias in our study. Clearly, patients with asymptomatic RSV infections would not seek medical advice, so the true incidence of respiratory tract infections due to RSV in LTRs could be higher.

Our observation of a high number of RSV-infected LTRs spontaneously evolving favorably contrasts with previous reports supporting early specific anti-RSV therapy (especially aerosolized ribavirin),[@bib5], [@bib6], [@bib18] and raises critical questions regarding the more aggressive therapeutic approaches recommended.[@bib20] According to our review of the 86 previously published cases of RSV infections among adult LTRs, our patients were not less immunosuppressed than those described elsewhere ([Table 3](#tbl3){ref-type="table"}). Previous studies suggested that severe RSV infections may occur early after transplantation when the immune response is most compromised.[@bib6] However, a more recent study reported only 24% of infections during the first 3 months post-transplantation.[@bib5] In our cohort, only 1 patient developed an RSV infection during the first 3 months post-transplantation. He evolved favorably without any specific therapy. Clearly, further studies are needed to determine whether time after transplantation impacts on the severity of disease and necessity of treatment.Table 3Selected Publications With References, Reporting Lower Respiratory Tract Infections Due to RSV in Lung Transplant Recipients (All Patients Symptomatic)Study (year)*n*Study designRadiologic abnormalitiesRSV detectionConcomitant pathologyRSV treatment[b](#tblfn1){ref-type="table-fn"}Mechanical ventilationOutcomeData from Allen et al[@bib43] (1986)1RetrospectiveNoBAL cultureNoSteroidsnoRecoveryData from Doud et al[@bib44] (1992)1RetrospectiveYesBAL cultureNoAerosolized ribavirinnoRecoveryData from Murris-Espin et al[@bib45] (1993)2Retrospective2/2FANoAerosolized ribavirin 2/2noRecovery 2/2Data from Wendt et al[@bib46] (1995)9RetrospectiveAt least 5/96 BAL cultures, 2 throat cultures, 1 sputum culture, 3 EIA1 EBV-related lymphproliferative disorder, 1 pneumonia due to *Pseudomonas aeruginosa*, 2 CMV in BALAerosolized ribavirin 8/9, 1 untreatedat least 1/9Recovery 8/9, death 1/9Data from Krinzman et al[@bib18] (1998)4Retrospective2/4BAL culture antigen, EIA1 bacterial sepsis?Aerosolized ribavirin 3/4, 1 untreatedNARecovery 3/4, death 1/4Data from Palmer et al[@bib6] (1998)5RetrospectiveNA, at least 1 chest radiography normalBAL culture FA1 *Pseudomonas aeruginosa* and *Aspergillus* pneumoniaAerosolized ribavirin 4/5, 1 untreated2/5Recovery 4/5, death 1/5Data from McCurdy et al[@bib5] (2003)14RetrospectiveAt least 12/1411 BAL culture, 6 EIA, 1 PCR1 *Haemophilus influenzae* pneumonia, 1 *Aspergillus*?, 1 acute rejection, 2 parainfluenzaAerosolized ribavirin 14/14At least 2/14Recovery 12/14, death 2/14Data from Khalifah et al[@bib28] (2004)4Retrospective4/4FA, BAL cultureNANANADeath 4/4Data from Glanville et al[@bib8] (2005)18ProspectiveNA18 FA, 14 culturesNoIntravenous ribavirin with steroids 18/18NoRecovery 18/18Data from Milstone et al[@bib1] (2006)8ProspectiveMaximal 6/85 PCR, 1 EIA, 1 culture, 7 serologyNoNANARecovery at least 7/8Data from Pelaez et al[@bib37] (2009)10ProspectiveNA10 culturesNo10 oral ribavirinNARecovery 10/10Present article10Retrospective3/103 PCR, 2 BAL cultures1 bacterial pneumonia, 1 asymptomatic CMV replication 1 CMV disease, 3 acute rejections2 ribavirin and palivizumab, 8 untreated1/10Recovery 10/10Summary869 retrospective, 2 prospective35/54 (65%)Mostly BAL culture49 aerosolized ribavirin, 2 intravenous ribavirin, 1 peroral ribavirin, 2 palivizumab, 13 untreated6/62 (10%)Recovery 76/86 (88%), death 10/80 (13%)[^2][^3][^4]

Both RSV infections and acute rejection episodes have been suggested to be risk factors for the development of BOS.[@bib7], [@bib8], [@bib29], [@bib30] It has also been suggested that RSV infections may trigger acute rejection.[@bib3], [@bib18], [@bib29] Strikingly, we observed post-RSV infection worsening of BOS stage in 60% of patients, during a mean follow-up time of 45 months. Interestingly, half of these patients also experienced ≥3 post-RSV acute rejection episodes. Because of the small number of cases, and confounding rejection episodes, it remains difficult to ascertain the potential responsibility of RSV infections in the development and/or worsening of BOS in our cohort. However, this warrants further investigation in large LTR cohorts. A possible causality between mild RSV infections that *per se* evolve favorably without specific treatment and BOS would potentially have major diagnostic and therapeutic implications. Indeed, such an association would support screening for RSV in LTRs, even those with mild symptoms. Moreover, one would have to establish in controlled trials whether specific anti-RSV treatment could prevent BOS worsening in such conditions.

One should not forget both the increased costs and potential adverse effects associated with specific RSV therapy. Immunoglobulins,[@bib31], [@bib32] ribavirin,[@bib33] and pavilizumab[@bib34], [@bib35] may all have significant adverse effects. In some studies the incidence of serious adverse effects of ribavirin was high, with hemolytic anemia occurring in 61% of treated patients.[@bib36] In our study, none of the 2 patients treated with ribavirin developed serious adverse effects. Likewise, Pelaez et al reported only 1 episode of mild reversible anemia among LTRs treated with oral ribavirin for RSV.[@bib37] They further suggested that oral ribavirin might be as efficient---but 20-fold less expensive---than nebulized ribavirin. Cost-effectiveness analyses for pavilizumab for the treatment of RSV infections in adults are missing. Such studies are presently available only for prophylaxis in infants,[@bib38], [@bib39] who require much smaller doses than adults.[@bib40]

In conclusion, our observations support that LTRs without severe disease due to RSV, and without particularly enhanced immunosuppression (eg, anti-thymocyte globulins), do not necessarily require specific anti-viral treatment. This contrasts with previous reports and expert opinions,[@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46] which favor early specific anti-RSV treatment in LTRs. However, most of these earlier studies were retrospective, included small numbers of patients, assessed several different respiratory viruses, and contained incomplete clinical information. Finally, many recommendations were derived from BMT recipients,[@bib4], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17] who represent a clinically distinct patient population. We therefore suggest that LTRs positive for RSV at least 3 months after transplantation, with only minor clinical symptoms, may be observed carefully with a transient reduction of immunosuppression, and that a specific anti-RSV treatment be initiated only in cases of clinical deterioration. However, a randomized clinical trial is warranted to determine whether this less aggressive, step-by-step approach is safe, and does not expose LTRs to an increased risk of BOS development.
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[^1]: AML, acute myeloid leukemia; BAL, bronchoalveolar lavage; CFU, colony forming units; COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in 1 second; MRSA, methicillin-resistant *Staphylococcus aureus*; PCR, polymerase chain reaction; RSV, respiratory syncytial virus.

[^2]: BAL, bronchoalveolar lavage; CMV, cytomegalovirus; EBV, Epstein-Barr virus; EIA, enzyme immunoassay test; FA, direct fluorescent antibody test; NA, not available; PCR, polymerase chain reaction; RSV, respiratory syncytial virus.

[^3]: ^a^Number of RSV episodes.

[^4]: Besides reduction of immunosuppression and supportive care.
